Coherus Oncology

Forecast & Rating7 analysts currently cover Coherus Oncology, with about 85.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $7.80, about 453.2% upside from the current price of $1.41. Price targets range from $4.00 to $12.00 — a wide spread, showing clear disagreement over just how much Coherus Oncology can rise. For you, this means most professionals who study Coherus Oncology closely still see room for the stock to rise. Data as of Jun 22, 2026; for reference only and not investment advice.